Optometrist · Vienna, WV
NPI
1659424877
Since 2007
Specialty
Optometrist
Code 152W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1500 Grand Central Ave, Suite 112
Vienna, WV, 26105
Phone (304) 295-5025
Groups this clinician bills Medicare through
Medicare paid, 2024
$103K
2,826 services
Medicare patients, 2024
382
Average age 76
Drug cost, 2024
$636K
1,391 prescriptions
Company payments, 2025
$883
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jill K Showalter was code 83861 (clinical chemistry), 861 times for 187 patients. In total Jill K Showalter billed 2,826 services in 20 codes, and Medicare paid $103K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 83861 Clinical Chemistry | Office | 861 | 187 | $22.03 | $19K |
| 83516 Immunoassay | Office | 756 | 165 | $11.30 | $8,543 |
| 99213 Office E&M - Established | Office | 435 | 200 | $59.37 | $26K |
| 92014 Ophthalmological E&M | Office | 234 | 224 | $73.86 | $17K |
| 92285 Standard X-ray | Office | 121 | 87 | $14.14 | $1,711 |
| 92133 Computerized Ophthalmic Imaging | Office | 106 | 74 | $22.41 | $2,375 |
| 68761 Eye | Office | 96 | 48 | $80.51 | $7,729 |
| 92134 Computerized Ophthalmic Imaging | Office | 63 | 53 | $22.16 | $1,396 |
| 99214 Office E&M - Established | Office | 38 | 36 | $80.57 | $3,062 |
| 92083 Vision, Hearing, and Speech Services | Office | 37 | 35 | $40.49 | $1,498 |
| 99212 Office E&M - Established | Office | 21 | 17 | $33.93 | $712 |
| 99203 Office E&M - New | Office | 11 | 11 | $76.17 | $838 |
By year: 2022 $115K for 2,667 services; 2023 $105K for 2,775 services; 2024 $103K for 2,826 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83861 Clinical Chemistry | 861 | 187 | $22.03 | $19K |
| 83516 Immunoassay | 756 | 165 | $11.30 | $8,543 |
Medicare prescription drug claims, 2024
In 2024, the drug Jill K Showalter prescribed most often to Medicare patients was Fluorometholone, with 209 prescriptions and refills. In total Jill K Showalter wrote 1,391 Medicare prescriptions that cost $636K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Fluorometholone Generic | 209 | 221 | 115 | $15K |
| Restasis Cyclosporine | 145 | 333 | 87 | $203K |
| Latanoprost Generic | 138 | 319 | 45 | $1,725 |
| Cequa Cyclosporine | 135 | 217 | 51 | $119K |
| Azelastine Hcl Generic | 84 | 142 | 36 | $1,963 |
| Loteprednol Etabonate Generic | 67 | 72 | 36 | $7,164 |
| Eysuvis Loteprednol Etabonate | 66 | 66 | 37 | $32K |
| Xiidra Lifitegrast | 61 | 134 | 29 | $89K |
| Epinastine Hcl Generic | 49 | 95 | 24 | $5,141 |
| Moxifloxacin Moxifloxacin Hcl | 43 | 43 | 19 | $2,198 |
| Xdemvy Lotilaner | 29 | 42 | 28 | $54K |
| Tyrvaya Varenicline Tartrate | 29 | 43 | Under 11 | $28K |
| Timolol Maleate Generic | 28 | 60 | Under 11 | $270 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 22 | 22 | 14 | $273 |
| Doxycycline Hyclate Generic | 22 | 28 | Under 11 | $427 |
Brand drugs: 831 claims; generic drugs: 560 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jill K Showalter $883 ($883 in general payments such as food, travel and fees) from 7 companies. The largest payer was Tarsus Pharmaceuticals, Inc. with $319.
| Company | Payments | Amount |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. TARS | 8 | $319 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 12 | $241 |
| Dompe US, Inc. | 1 | $123 |
| Bausch & Lomb Americas Inc. BLCO | 2 | $115 |
| Mallinckrodt Hospital Products Inc. | 2 | $51.39 |
| Abbvie Inc. ABBV | 1 | $17.13 |
| Thea Pharma Inc. | 1 | $16.44 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.